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Obesity has become one of the main threats to health worldwide and therefore gained
increasing clinical and economic significance as well as scientific attention. General
adipose-tissue accumulation in obesity is associated with systemically increased pro-
inflammatory mediators and humoral and cellular changes within this compartment.These
adipose-tissue changes and their systemic consequences led to the concept of obesity as
a chronic inflammatory state. A pathognomonic feature of Crohn’s disease (CD) is creeping
fat (CF), a locally restricted hyperplasia of the mesenteric fat adjacent to the inflamed seg-
ments of the intestine. The precise role of this adipose-tissue and its mediators remains
controversial, and ongoing work will have to define whether this compartment is protecting
from or contributing to disease activity.This review aims to outline specific cellular changes
within the adipose-tissue, occurring in either obesity or CF. Hence the potential impact of
adipocytes and resident immune cells from the innate and adaptive immune system will
be discussed for both diseases. The second part focuses on the impact of generalized
adipose-tissue accumulation in obesity, respectively on the locally restricted form in CD,
on intestinal inflammation and on the closely related integrity of the mucosal barrier.
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INTRODUCTION
Obesity has become one of the main threats to health worldwide
and is outpacing smoking as the primary health hazard (1–4). Due
to the increasing clinical and economic significance, fat-tissue has
attracted growing scientific attention. Once only recognized as
storage for energy, today adipose-tissue is acknowledged as an
endocrine organ with multiple functions (5, 6).
The extent of the fat storage is inter individually highly variable
and ranges from 5 to 60% of the total body weight. Adipose-tissue
is divided into subcutaneous and visceral fat (7).
Several studies reported morphological and functional differ-
ences between these adipose-tissue compartments. At least in parts
the depot-difference between visceral and subcutaneous fat can be
explained by a distinct expression of developmental genes and dif-
ferent adipocyte progenitor cells (8–10). Characteristics of both
fat depots are summarized in Table 1.
In obesity, a significant expansion of the entire fat-tissue
takes place with distinct alterations within the cellular, humoral,
and stromal compartment (11–13). The production of pro-
inflammatory mediators and the immune-cell infiltration is
increased in adipose-tissue of obese compared to lean individuals
(5, 6). These adipose-tissue changes and their systemic conse-
quences led to the concept of obesity as a chronic inflamma-
tory state (14). The chronic inflammation results in secondary
diseases in the long run and impacts the progression of other ill-
nesses. Especially, visceral adiposity is associated with the develop-
ment of insulin resistance and correlates strongly with metabolic
syndrome (15–17).
Fat accumulation can also be locally restricted. A body
weight-independent characteristic hyperplasia of the mesenteric
fat-tissue frequently occurs in Crohn’s disease (CD). This so-called
creeping fat (CF) enwraps the inflamed segments of the gut and
covers more than 50% of the intestinal circumference. Connect-
ing fat accumulation and inflammatory activity, CF correlates
with transmural inflammation, fibrosis, muscular hypertrophy,
and stricture formation (18–20). Humoral and cellular alterations
within the CF are unique and differ from those observed in
hypertrophied fat-tissues in obesity (20–22) (Figure 1).
While the existence of CF has been described at the beginning
of the last century, the cause of this phenomenon is still unclear.
There is increasing data pointing to a connection between
bacterial translocation and the development of CF. Even in the
healthy gut bacterial translocation occurs (23, 24), but it is strongly
increased in CD (19, 25). Bacteria can trigger adipocytes and
preadipocytes proliferation in vitro (26). Thus one might spec-
ulate, which aggrandized bacterial translocation leads to adipose-
tissue hyperplasia in CD (19, 25). Recently, nucleotide-binding
oligomerization domain (NOD) variations have been shown to
influence adipocyte differentiation. Interestingly, NOD2 variants,
which are associated with a higher susceptibility to CD, affect
bacterial translocation (27). In CD patients, bacterial mRNA is
increased in patients carrying bacterial mRNA compared to con-
trols and the amount of bacterial DNA is related to disease activity.
Unfortunately, the author of the study did not give any informa-
tion regarding the mesenteric fat of these patients. Nevertheless
bacteria passing though the intestinal barrier are likely to end
up in the mesenteric fat close by, where they might trigger CF
development (28).
While the connection between obesity, metabolic, and vas-
cular diseases has been studied intensively, the link between
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Table 1 | Adipose tissue depots.
Subcutaneous adipose tissue (SAT) Visceral adipose tissue (VAT)
Percentage of the total body
fat (7, 142)
∼80% ♂ 10–20%♀ 5–10%
The absolute amount of VAT increases with age in both genders
Main depots (7) - Abdominal Retro-peritoneal
- Gluteal Intra-peritoneal (omental; mesenteric; epiploic)
- Femoral
Venous drainage Dependent on anatomical location Portal vein
Morphological and functional
characteristics (7, 9, 142–151)
- Consists of more preadipocytes per (gram) tissue - Higher vascularization
- Higher expression of leptin and CXCL -10 - Greater immune-cell content
- Adipocytes have an increased metabolic (both lipogenesis and
lipolysis) activity
- Higher expression of pro-inflammatory cytokines (IL-6, IL-8,
MCP-1, RANTES, MIP-1α, and PAI-1)
- Higher adiponectin expression
- Higher expression of molecules from innate immunity, acute
phase response and complement factors, angiotensinogen, and
Plasminogen activator inhibitors-1
- Omentin expression
Metabolic implications (9,
144, 147, 152, 153)
- Adipocytes have a higher insulin sensitivity - Increase is associated with insulin resistance and metabolic
syndrome- Higher adipogenic ability of the stem cell
compartment
- Higher intake capacity for free fatty acids and
triglycerides
- Major metabolic buffer until a certain “tipping
point”→SAT becomes disfunctional due to a
positive caloric balance with adipocyte
hypertrophy, decreased adipogenesis, and
angiogenesis
- Adipose tissue stem cells over express CD105, Fgf2, and notch
target genes
- Surgical removal of VAT in rodents improves insulin sensitivity
- Diet and exercise cause preferential fat loss from VAT than SAT
fat accumulation and intestinal inflammation is relatively new.
This review aims to examine the association between (intesti-
nal) inflammation and fat accumulation in general and as a local
phenomenon. While adipocyte hypertrophy/hyperplasia is accom-
panied by humoral and cellular changes within the tissue, we par-
ticularly discuss the cellular compartments including adipocytes
and resident/infiltrating immune cells to define the characteristics
of CF versus fat-tissue in obesity.
ALTERATIONS OF FAT-TISSUE COMPOSITION IN OBESITY
AND CROHN’S DISEASE
ADIPOCYTES
Adipocytes are divided into brown, beige, and white cells presum-
ably covering diverse intermediate forms. White fat cells represent
the main type in adipose-tissues of adults (29, 30) therefore this
review will focus in this part. Mature white adipocytes contain a
large internal fat droplet marginalizing the remaining cytoplasm
and nucleus. Adipocytes store the body’s energy supplies, actively
produce various mediators and are characterized by their cellular
plasticity (31).
Remarkably, the absolute adipocyte number seems to be genet-
ically determined and does not change significantly after the end
of the growth phase (32). Tissue enlargement in obesity is pri-
marily due to cellular hypertrophy, rarely to hyperplasia. Enlarged
adipocytes in obesity have altered secretory activity with high pro-
duction of pro-inflammatory cytokines and leptin. Additionally
their triglyceride storage is increased (33, 34).
In contrast, CF is a result of adipose-tissue hyperplasia; the
adipocytes are significantly smaller and their number is four times
increased compared to normal mesenteric fat-tissue (18). While
the morphologic changes take place in the adipose-tissue adjacent
to the inflamed intestine, the gene expression profile is even altered
in visceral fat distant from the inflamed intestinal segment. In obe-
sity especially pro-inflammatory genes are up-regulated, whereas,
visceral adipocytes of CD patients show characteristic patterns of
increased pro- and anti-inflammatory gene expression (35). In
line with this, smaller adipocytes produce less pro-inflammatory
mediators (33) and, once activated, adipocytes from the CF are less
responsive toward further stimulation (36, 37). Nevertheless, they
are highly active producers of different mediators, with significant
over-expression of leptin, adiponectin, and resistin as well as of
different cytokines and chemokines (22, 38) (Figure 1).
Limiting translation from animal models of intestinal inflam-
mation to human disease, none of the available models show
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FIGURE 1 | Adipose tissue morphology and expression profile-
differences in obesity and CD. (A) Obesity is defined by a general
enlargement of adipose tissue. Especially, the visceral fat-tissue
undergoes drastic humoral and cellular changes in obese compared to
lean individuals. In Crohn’s disease (CD), adipose tissue accumulation is
localized around the inflamed intestinal segments. The interplay between
adipose tissue and immune cells during inflammation within the tissue is
the subject of ongoing research. Given the differences between adipose
tissue in CD and obesity, obese CD patients’ adipose tissue might have
varying impact on the intestinal inflammation depending on its
localization and reason of development. The different adipose tissue
morphology and composition between obesity and creeping fat is
illustrated in (B). Adipocytes in obesity are hypertrophic and up-regulate
pro-inflammatory mediators. Additionally, the immune-cell compartment
within the tissue changes to deprived modulatory/anti-inflammatory cells
and increased pro-inflammatory immune cells. Creeping fat is
characterized by small hyperplastic adipocytes, with enhanced
expression of pro- as well as anti-inflammatory mediators and genes.
This is also mirrored in a more balanced increase of different immune
cells within the tissue.
CF-tissue. Still some interesting observation have been made: even
though adipose-tissue accumulation does not occur, mononuclear
cells infiltrate the mesenteric fat-tissue, adipocyte size decreases,
and fibrotic structures appear adjacent to the inflamed murine
intestine during acute colitis. Furthermore, mRNA expression
of tumor necrosis factor (TNF)α, interleukin (IL)-1β, and IL-6
are up-regulated (39). In trinitrobenzenesulfonic acid-induced
colitis in mice and rats TNFα and IL-10 in the mesenteric
fat is increased while leptin and adiponectin release is not
altered compared to healthy animals (40, 41). Experimental col-
itis by dinitrobenzenesulfonic acid in Balb/c mice Olivier et al.
aimed to establish a model for CF. They successfully induces
adipose-tissue accumulation surrounding the ulcerated areas of
the inflamed colon (32). This fat accumulation correlated with
inflammatory activity and was strictly limited to severe coli-
tis. In contrast to CD patients, animals with less inflamma-
tion or regression of their colitis did not show any signs of
CF. The hypertrophic mesenteric fat in mice showed high con-
centrations of IL-6 and monocyte chemotactic protein (MCP)-
1 but low adiponectin and leptin levels. Since locally elevated
adipokine concentrations are considered hallmarks for the CF,
also this model does not completely reflect the distinct char-
acteristics of human CF (42). More recently was shown that
in moderately active colitis induced by dinitrobenzenesulfonic
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Table 2 | Immune-cell characterization in obesity versus Crohn’s
disease.
Immune cells Obesity Crohn’s
diseasea
Rodents Men Men
Macrophages
- M1 ↑↑ ↑ In crown-like structures ↑
- M2 ↓ ↑↑ ↑↑
Granulocytes
- Eosinophil ↓ n.d. n.d.
- Neutrophil ↑ n.d. n.d.
ILC
- NK n.d. ↑ In activated CD56bright n.d.
- ILC2 ↓ n.d. n.d.
T cells ↑ ↑ ↑
- NKT ↓ ↓ n.d.
- CD4+ Th1 ↑ ↑ n.d.
- CD4+ Th2 ↓ n.d. n.d.
- CD4+ Th17 ↓ n.d. n.d.
- CD8+ ↑ n.d. n.d.
- Regulatory FoxP3+ ↓ ↓/↑ n.d.
aNo “Rodents” column due to missing immune cells in mesenteric fat-tissue of
animal models for Crohn’s disease.
n.d., To our best knowledge not done yet.
acid or dextran sodium sulfate reduced mesenteric fat-tissue
was accompanied by increased IL-6 and MCP-1 but decreased
adiponectin expression (43).
Besides adipocytes, preadipocytes, stroma cells, and various
immune cells are found within the adipose-tissue. Cells of the
innate and of the adaptive immune system infiltrate this com-
partment and their composition changes dependent of the body
constitution (44) (Table 2). We again focus on the most relevant
cell populations for obesity and CD.
ADIPOSE-TISSUE MACROPHAGES
Macrophages are a heterogeneous cell population, roughly divided
into the classically activated, pro-inflammatory M1 and the alter-
natively activated, immune modulatory M2 subtype, representing
two ends of a broad spectrum of plasticity (45, 46). Tissue-
resident macrophages are strongly influenced by their environ-
ment (47, 48).
Murine adipose-tissue macrophages (ATM) are characterized
by high CD14, IL-10, and arginase 1 expression (49). In humans,
a broad receptor-expression including the mannose receptor
(CD206), various scavenger receptors as well as adhesion mole-
cules like CD163, αvβ5 integrin, CD209, CD200, CD1b, and CD1c
has been described for ATM. These macrophages showed high
scavenger activity and significant IL-10 and IL-1 receptor antag-
onist production. In contrast to the “anti-inflammatory” pheno-
type of some in vitro-polarized M2-macrophages, ATM produce
large amounts of pro-inflammatory cytokines including TNFα in
response to stimulation with either Toll-like receptor ligands or
interferon-γ (50, 51). In summary, ATM show an M2 phenotype
with pro-inflammatory properties (50, 51).
In obesity and in CD, macrophages accumulate in adipose-
tissues. The accumulation within the fat represents an early event
in obesity in mice and men (52–54). ATM are a major source
of pro-inflammatory mediators in obesity and contribute signif-
icantly to the systemic inflammatory status (12, 55–58). ATM
can inhibit the effect of insulin in adipocytes leading to sys-
temic insulin resistance via endocrine signaling (54, 59–62). Hence
ATM strongly contribute to inflammatory as well as to metabolic
consequences of obesity.
Lymphocyte antigen (Ly) 6Chigh monocytes in the circulation
(comparable to CD14+ cells in humans) are rapidly recruited
to inflammatory sites and sites of tissue remodeling (47). They
give rise to monocyte-derived macrophages and dendritic cells.
Withal tissue-resident macrophages have to be distinguished from
freshly recruited monocytes that differentiate depending on the
local milieu (47). Which factors recruit cells into the adipose-tissue
and direct polarization of monocytes into their various subsets is
not fully understood yet. But ATM accumulation is clearly associ-
ated with increased chemokine and adipokine production within
the adipose-tissue (63, 64). Especially, MCP-1/CCL2 recruits
macrophages into this compartment contributing to insulin resis-
tance (63). Pointing to additional mediators/mechanisms for ATM
recruitment, CC-motif receptor (CCR)2-deficiency does not suf-
fice to reduce ATM number and insulin resistance in obese mice
(64, 65). CCR5 has also been associated with adipose-tissue
inflammation and insulin resistance in mice (66). CXC-motif
ligand (CXCL)12, which is increased in diet-induced obesity facil-
itates ATM recruitment. Blocking the corresponding receptor
CXC-motif receptor (CXCR)4 resulted in reduced macrophage
accumulation and cytokine release (67). As part of a positive
feedback loop between adipose-tissue and bone marrow, adipose-
tissue-derived mediators like IL-1β, induce myeloproliferation and
monocyte development, contributing to the macrophage accumu-
lation (68). Also hypoxia due to cell hypertrophy takes part in
macrophage infiltration in obesity (69, 70). Recently, local pro-
liferation of macrophages within the fat was discovered (71–73).
Since only a subset proliferates (74), this does not seem to be the
main source of ATM accumulation (73).
It has been known for a while that diet-induced obesity gives
rise to a phenotype switch from M2 dominance to that of M1
macrophages in the visceral adipose-tissue of obese mice (49).
These macrophages express the M1 markers IL-6, CD11c along
with the inducible NO synthase (iNOS) and are typically arranged
in crown-like structures around necrotic adipocytes (49, 75, 76).
Human studies regarding ATM alterations in obesity provide
contradicting results. On one hand ATM from subcutaneous
fat-tissue of obese subjects produce pro-inflammatory mark-
ers (57, 77) regressing with weight loss (57, 77, 78). On the
other hand M2c-like macrophages with high fibrotic activity and
CD150 expression outnumber M1 macrophages forming crown-
like structures in the subcutaneous fat of obese patients (79). Cor-
respondingly, ATM from the subcutaneous fat of obese patients
were recently found to highly express the anti-inflammatory mark-
ers CD163 and IL-10, while TNFα and IL-6 were reduced com-
pared to lean individuals. Since pro-inflammatory markers were
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equally enhanced, the authors concluded that the adipose-tissue of
obese subjects remains more inflamed than in lean subjects (80).
Comparing subcutaneous and visceral fat-tissue, a minor sub-
group of ATM localizes within the crown-like structures and the
majority appears randomly distributed within the tissues (81).
Macrophages in crown-like structures are CD206+CD11c+ and
show features of both subgroups. The other ATM are CD206+,
CD34+ and positive for multiple scavenger receptors but do
not express CD11c suggesting their involvement in tissue repair
and maintenance. Remarkably, only the amount of CD11c+ cells
correlated with insulin resistance (81).
A distinct macrophage accumulation is also characteristic
for the CF. Although iNOS+ M1 macrophages are increased,
a far greater accumulation of CD163+ and stabilin 1+ M2-
macrophages suggests a domination of these cells in the CF (82).
Specific functions of this cell population are not known so far but
in vitro data suggest that resident macrophages are strongly influ-
enced by locally increased adipokine levels. Leptin and adiponectin
might favor the M2 subtype with high secretory activity for
pro- and anti-inflammatory chemokines and cytokines within the
CF (82, 83).
GRANULOCYTES
While macrophages are by far the best characterized immune
cells in adipose-tissues, eosinophil granulocytes recently have
gained attention. In lean mice, they represent around 5% of
the adipose-tissue cells, with decreasing percentages in obesity
(84). Eosinophils have been found to substantially modulate
adipose-tissue inflammation. Being potent producers of IL-4 and
IL-13, they support M2-macrophage polarization and thereby
impact glucose homeostasis (84, 85). In obese mice, numbers of
eosinophils and M2-macrophages are dramatically reduced within
the adipose-tissue. Accordingly, eosinophil-deficient mice have
been characterized by high body-fat percentages and metabolic
deficiencies like impaired glucose tolerance (84). Eosinophils seem
to affect beige progenitors adipocytes and are involved in adap-
tation of WAT depots to thermogenic challenges (86). However,
their recruitment into the fat and their specific function has yet to
be elucidated (86). To our knowledge, neither the distribution of
eosinophils in adipose-tissues of obese individuals nor in the CF
has been studied yet.
Neutrophil granulocytes are rarely found in visceral fat of
lean mice but are rapidly recruited into the visceral fat in obe-
sity and seem to take part in impaired insulin sensitivity (87).
With neutrophil recruitment as a fast acute response in inflam-
matory processes in general and the neutrophil chemoattractant
IL-8 produced by activated adipocytes and polarized macrophages,
recruiting neutrophils is likely to be part of the adipose-tissue
inflammation in humans (82, 87). Again, their specific impact in
human adipose-tissue inflammation and the generation of CF is
not known so far.
INNATE LYMPHOID CELLS
Innate lymphoid cells (ILC), cells from the lymphoid line lacking
antigen specificity, represent a recently described cell population
within the adipose-tissue (88, 89). They are currently classified
based on their cytokine expression and specific transcription
factors (90). The first group is innate effectors cells with cyto-
toxic activity comprising natural-killer (NK) and ILC1 cells (91).
ILC2, also called natural helper cells, are defined by their pro-
duction of type-2 cytokines such as IL-4, IL-5, and IL-13 and
by the transcription factor GATA3 (92–94). The third group
includes ILC3 and lymphoid-tissue inducer (LTi) cells. ILC3
express the NK-cell-activating receptor 46 and RORγt. In con-
trast to ILC1 cells they do not produce cytotoxic mediators.
This subgroup is mainly found in the mucosa of the intestine.
ILC3 as well as LTi have been shown to produce IL-17A and
IL-22 (91, 94).
Especially, ILC2 cells seem to be critical in adipose-tissue home-
ostasis (84). By producing IL-5 and IL-13 they recruit eosinophils
and M2-macrophages into adipose-tissues (89). Interestingly, IL-
25 treatment increased the numbers of ILC2 cells in adipose-tissue
of obese mice leading to weight loss and improved glucose toler-
ance (88). Data on ILC2 in human adipose-tissue are lacking at
this point.
A little more is known about NK-cells in fat. NK-cells are cate-
gorized according to the intensity of CD56 expression. CD56bright
cells are predisposed for IFNγ production and express tissue-
homing receptors, whereas, CD56dim cells are present in the
peripheral blood and mediate cytotoxicity (95, 96). While num-
bers of circulating NK-cells are altered in obesity, the number of
resident cells in fat-tissues does not change (97). However, the
proportion of CD56bright cells within the total NK-cell population
seems to be increased in obese subjects and to highly express the
activating receptor NKG2D. This activated NK phenotype might
indicate their significance for adipose-tissue inflammation that
requires further investigation (98).
T CELL COMPARTMENT
Natural-killer T cells
From their innate siblings to the adaptive equivalent: natural-
killer T (NKT) cells represent a link between innate and adaptive
immunity. Lynch recently provided a detailed overview about their
significance in human and murine adipose-tissue (99). NKT cells
are divided into type I and type II NKT cells. The well character-
ized type I NKT cells, also called invariant NKT (iNKT) cells are
present in healthy human and murine adipose-tissue. They rec-
ognize lipid antigens independent of MHC II via CD1d-restricted
presentation by antigen-presenting cells. Upon activation, iNKT
cells are fast and potent producers of different chemokines that
due to their strong cytotoxic impact activate other immune cells
and contribute to anti-tumor activity (99). iNKT cells are primar-
ily tissue-resident cells and comprise T-helper (Th)1-, Th2-, and
Th17-like iNKT subsets, whose phenotype and function depends
on the local milieu (100, 101). Most adipose-tissue iNKT are
CD4−, NK1.1−, and Th2-polarized cells with regulatory potential
and high IL-10 expression (102, 103).
Obesity leads to a decrease of adipose-tissue iNKT in humans
and rodents that normally protect from diet-induced obesity
and secondary diseases (102–106). By producing regulatory
cytokines, enhancing anti-inflammatory macrophages and affect-
ing adipocyte function iNKT cells induce weight loss, and improve
fatty liver disease and insulin resistance (105). NKT cell-deficient
mice are more susceptible to health risks associated with high-fat
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diet (HFD) as indicated a fast increase in weight and reduced
physical activity (107).
The role of type II NKT cells in adipose-tissue and in obesity-
related diseases is less well defined. Even though CD1d−/− mice
lacking both NKT populations gain weight and develop metabolic
problems, it has been suggested that type II NKT cells are involved
in the induction of adipose-tissue inflammation (88, 89). Treat-
ment with IL-25 known to induce ILC2 expansion, resulted in
increased infiltration of iNKT and type II NKT cells as well as
of other immune cells within the adipose-tissue of obese mice.
These cellular changes were accompanied by weight loss and
improved glucose tolerance (88). While studies emphasize a pro-
tective function for NKT cells regarding obesity and its metabolic
consequences, the ultimate proof remains to be provided.
T-helper cells
In lean individuals about 10% of the cellular compartment of
adipose-tissue consists of CD3+ lymphocytes, predominantly of
CD4+ Th2 or CD4+CD25+ forkhead box protein 3+ regulatory T
cells (Treg) (108). However, in obese mice the ratio of CD8+ and
CD4+ T cells is shifted toward CD8+ cytotoxic T cells. Within the
CD4+ lineage Th17 cells as well as Treg are profoundly reduced
resulting in a dominance of Th1 cells in this compartment. Sup-
porting this, the absolute cell numbers of Th1 cells are about
threefold higher in the visceral fat of diet-induced obese mice
as compared to lean controls (108).
In obese humans, the overall number of adipose-tissue T cells
is increased (109–111), with a dominance of Th1 over Treg. The
ratio correlates with the body mass index (BMI) and changes from
6:1 in lean to 12:1 in obese individuals (112). A positive correlation
between the T cell count in adipose-tissue and the BMI of diabetes
patients suggests an involvement of these cells in obesity-related
metabolic diseases (13, 14).
Regulatory T cells
The impact of adipose-tissue Treg has been studied intensively.
In lean individuals, Treg accumulate in VF but not in SF (108,
113). Compared to Treg from other organs adipose-tissue Treg
have a distinct GATA3+, CCR2+, KLRG1+, and CD103− pheno-
type with over-expression of CCR1, CCR2, CCR3, CCR5, CCR9,
CXCR6, and down-regulation of CCR6, CCR7, CXCR3 (108,
113). Repeated T cell receptor clones are highly suggestive for an
adipose-tissue-specific antigen. Besides chemotaxis, e.g., receptor
equipment, adipokines, and macrophage-derived mediators seem
to contribute to Treg accumulation in the visceral adipose-tissue
(108, 113, 114). From a mechanistic point of view, the peroxi-
some proliferator-activated receptor PPARγ represents a central
regulatory pathway for Treg infiltration into the visceral fat (115).
In healthy lean individuals, approximately 15% of the CD4+ T
cells are Treg; in some inflammatory conditions or malignancies
this proportion can increase up to 40% (108, 113, 114). In con-
trast, as shown in several animal models obesity is accompanied
by a pronounced decline of adipose-tissue Treg. The chemokine
receptor-expression is altered in adipose-tissue Treg of obese mice
with down-regulated CCR1, CCR2, and CXCR6 but increased
CXCR3 expression (114). Loss of Treg was associated with higher
insulin resistance and risk for diabetes mellitus in these animals
(11, 108, 116, 117). Interestingly, aging per se seems to reduce the
numbers of adipose-tissue Treg paralleled by an increased risk
for insulin resistance even in lean mice (114). The anti-diabetic
PPARγ agonist pioglitazone increases the Treg numbers in the vis-
ceral fat of lean and obese mice (116) underlining that current
anti-diabetic treatment directly relies on Treg control (114).
While murine adipose-tissue Treg have been analyzed in detail,
little is known about their human counterparts and the results
are somewhat conflicting. Three studies found a BMI-dependent
decrease of CD4+FoxP3+ adipose-tissue Treg in the visceral fat of
obese humans (11, 108, 112). Zeyda et al. detected higher FoxP3
expression in the same location (118). Treg are involved in gut
homeostasis, mucosal integrity, and tolerance (119). While the
frequency of Treg in the peripheral blood of patients with inflam-
matory bowel diseases (IBD) is low, their number is increased
within the inflamed mucosa (120, 121). To our knowledge Treg
within the adjacent CF have not been quantified yet. With respect
to their significance in visceral fat as well as their potential role in
IBD further studies regarding this subject are required. Of special
interest is that IL-6 can convert Treg into IL-17 producing cells
(122) – two cytokines suggested to play a dominant role in the
pathogenesis of IBD (123).
To sum up, adipose-tissue hypertrophy is accompanied by pro-
found changes within the resident immune-cell compartment,
leading from homeostasis toward a pro-inflammatory local envi-
ronment. In obesity, these changes have been associated with sys-
temic inflammation and contribute to insulin resistance and type-
2 diabetes (49, 75, 87, 102–104, 108, 112). Thus, the inflammatory
status of adipose-tissue depends on different factors including
location and composition of immune-cell compartments. The last
one is strongly influenced by weight gain and obesity resulting in a
shift from a homeostatic regulatory environment comprising M2-
macrophages, eosinophil granulocytes, NKT cells, and CD4+ Treg
toward a more pro-inflammatory environment characterized by a
dominance of M1 macrophages and a T cell compartment altered
toward CD4+ Th1 and CD8+ cytotoxic subtypes. How these
changes are initiated and which individuals are mainly affected
remains to be explored.
Having summarized, the current knowledge of the cellular
compartment within the adipose-tissue, the last section of this
review will serve to outline the interplay of the intestine and the
mesenteric fat-tissue.
OBESITY AND BARRIER DEFECT
The mucosal barrier consisting of the different cells within the
epithelia layer and lamina propria, including (resident) immune
cells as well as their cellular products (e.g., mucus, defensins, and
cytokines), allows for the absorption of nutritional factors but
prevent from increased translocation of bacteria and viruses. Obe-
sity alone seems to suffice to induce an impaired barrier function
and intestinal inflammation in rodents (124–126). HFD facilitates
translocation of intestinal bacteria and thereby triggers low-grade
inflammation in obesity. Emphasizing that the intestinal micro-
biota forms a prerequisite for the effect of HFD, induced TNFα
mRNA and nuclear factor-κB activation was only found in the
intestine of specific pathogen free but not of germfree mice (113).
In line with these observations, ileal TNFα mRNA expression
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correlated to weight gain, obesity, and insulin resistance in mice
(124). HFD not only affect the microbiota composition in mice
with reduced Lactobacillus and increased Oscillibacter species but
equally results in elevated intestinal permeability due to alterations
in tight-junction proteins accompanied by a low transepithelial
resistance contributing to the barrier defect. In consequence, the
mesenteric fat is infiltrated by large numbers of macrophages
and associated up-regulation of pro-inflammatory molecules like
IL-6 and TNFα (125). These obesity-driven changes are not
restricted to dietary-induced obesity. In two genetically driven
obese mouse models mucosal barrier defects were concomitant
with the increase of bacterial endotoxin and pro-inflammatory
cytokines in the portal blood (126).
Taken together these data suggest that the intestinal bar-
rier influenced by genetic risk factors, microbiota, and nutri-
tional factors exert a substantial impact on the development of
adipose-tissue inflammation in obesity.
While in obesity mucosal barrier is only mildly affected, CD
is characterized by a transmural inflammation with subsequent
destruction of the intestinal barrier.
OBESITY AND CROHN’S DISEASE
Even though CD patients rather have normal or subnormal BMI,
obesity has become an increasing problem even in this patient
collective (127). Whether obesity is a risk factor for CD has not
been conclusively answered. A study with 524 obese IBD patients
of all ages found a slightly higher risk for developing CD but not
for ulcerative colitis. The association was strong for older patients
where the influence of environmental factors is expected to be
more pronounced in general (128). A European prospective cohort
study did not associate obesity to an increased risk of developing
CD (129).
Once CD has been established, the course of disease is sig-
nificantly altered by the patient’s constitution. Overweight CD
patients are more prone to active disease and show more frequent
anorectal involvement. Consequently, the hospitalization rate is
higher and the time until the first surgery is shorter in overweight
CD patients compared to lean individuals (128, 130–132). How-
ever, there seems to be no significant difference between the overall
number of surgical interventions (128, 132, 133).
While children with CD typically present with weight loss and
growth retardation, a recent study including nearly 1600 children
indicates that approximately 20% of the children with CD were
overweight or obese. The rate of obesity in children with ulcera-
tive colitis was 30% and thus comparable to the general population
(134). Different from the adult population obesity, had no signif-
icant effect on the short-term clinical outcomes of IBD with any
perceived difference in disease severity, short-term complications,
emergent admissions, or the need for surgical intervention in chil-
dren. Nevertheless obesity does increase the risk of urinary tract
infections and central venous catheter infection in pediatric IBD
patients (135).
Besides the progression of disease, also response to therapy
seems to be different when comparing lean and obese CD patients.
First evidence has been provided by a small single center study that
observed a higher risk for loss of response to adalimumab, but
not to infliximab treatment of CD in obese patients. The authors
hypothesize that the increased body-fat content impairs the effi-
ciency due to changed pharmacokinetic properties. Addition-
ally, high concentrations of circulating pro-inflammatory mole-
cules also altering the therapeutic effect led to the conclusion,
which weight-adjusted anti-TNF therapy should be favored in
obese patients (136). Using this approach for infliximab treat-
ment did not overcome the shorter time to loss of response in
obese IBD patients compared to lean controls, suggesting that
weight-adjusted therapy alone is not sufficient (137); a phenom-
enon also observed in obese spondyloarthritis patients receiving
weight-adjusted infliximab therapy (138).
DIET VERSUS OBESITY – WHAT DRIVES INFLAMMATION?
As mentioned above, HFD followed by weight gain induces intesti-
nal barrier alterations. Thus not only the events within the fat-
tissue and their systemic impact, but also the factors leading to
obesity might directly influence inflammatory processes in CD.
Especially western (high-fat) diet affects intestinal inflammation
in multiple ways from luminal microbiota composition to antigen
presentation and change in prostaglandin balance. In a systematic
review, Hou et al. outlined the association between pre-diagnosis
dietary intake and the risk of developing IBD (139). A higher risk
for ulcerative colitis or CD associates with HFD, the increased
intake of polyunsaturated fatty acids, omega-6 fatty acids, and
meats; and also with saturated fatty acids in CD. While high intake
of dietary fiber and fruits decreased the risk of developing CD,
ulcerative colitis remained unaffected (139).
Data from animal models support these observations. HFD
enhanced intestinal inflammation in a mouse model of exper-
imental colitis (140). Particularly palm-oil based HFD fed to
TNF∆ARE/WT mice did not only aggravate intestinal inflamma-
tion but promoted expansion of inflammation into the proximal
colon, which seems to be of significance given the increased inci-
dence of colonic disease in obese CD patients (127). In this study,
disease severity was not associated with development of obe-
sity or metabolic dysfunction, which led to the conclusion that
the increased inflammatory activity might not be related to obe-
sity per se but is rather induced by the diet itself. Gruber et al.
emphasized dietary lipids and so-called metabolic endotoxemia as
causes for increased intestinal permeability and pro-inflammatory
immune-cell responses (140).
A direct impact on microbiological composition with a rise
in the proportion of sulfite-reducing pathobiont bacteria (e.g.,
Bilophila wadsworthia) has been shown for a HFD with mainly
saturated fatty acids. These specific bacterial changes were associ-
ated with a pro-inflammatory Th1-driven immune response. This
diet led to a higher incidence of colitis in genetically susceptible
IL-10−/− mice as well as in dextran sulfate sodium -induced col-
itis. By altering the intraluminal conditions (e.g., host bile acids)
saturated fatty acids within the western diet may induce dysbiosis
and thereby facilitate an increased inflammatory activity (141).
CONCLUSION
Adipose-tissue and its resident cells seem to be highly adaptable
and functionally depending on location, cellular composition and
dissemination. While obesity is characterized by a widespread
increase of adipose-tissue hypertrophy, the fat accumulation in
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CD is localized and independent of the body weight. Hyper-
trophic adipocytes have a pro-inflammatory gene expression
profile and produce large amounts of pro-inflammatory medi-
ators. Additionally, resident immune cells within the hyper-
trophic fat-tissue in obesity are primed toward a more pro-
inflammatory subtype. These adipose-tissue changes have sys-
temic consequences including elevated serum levels of pro-
inflammatory cytokines, C-reactive protein, and leptin. In this
way, adipose-tissue inflammation contributes to the development
of secondary diseases like diabetes and hypertension in obese
individuals.
In contrast secretory adipose-tissue changes in CD seem to be
rather focused to the mesenteric fat body. However, a systemic
impact can be equally suggested, since C-reactive protein that is
found increased systemically in active disease, can be produced by
the mesenteric fat-tissue. Interestingly, adipokine levels are only
locally elevated. Yet, the gene expression profile as well as medi-
ator secretion of small adipocytes within the CF is characterized
by both anti- as well as pro-inflammatory capacities, pointing to a
more balanced situation within the fat-tissue. Thus adipose-tissue
inflammation in the CF might directly modulate, possible even
control, intestinal inflammation.
While there are convincing mouse data to adipose-tissue
changes in obesity, human data are still rare. Especially in regard to
the differences between mouse and man (e.g., macrophage distri-
bution in adipose-tissue) there is a need for comparative studies.
Additional studies are required to characterize resident immune
cells within the fat in inflammatory conditions especially in the
visceral and CF. While knowledge about alterations in obese indi-
viduals might help to reveal novel strategies for the fight against
obesity, a better understanding of the role of the adipose-tissue
might also help to define novel therapeutic strategies for CD.
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